Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$1.45 -2.5%	$1.48	$1.10 ▼ $2.43	$82.70M	2.92	142,655 shs	50,843 shs
JATT JATT Acquisition	$1.15 -2.5%	$1.21	$7.80 ▼ $12.38	$19.84M	N/A	41,322 shs	242,896 shs
XBIT XBiotech	$2.80 -2.4%	$2.85	$2.50 ▼ $8.32	$87.50M	0.97	78,714 shs	2.50 million shs
ZURA Zura Bio	$1.05 -8.7%	$1.21	$0.97 ▼ $5.07	$78.63M	-0.12	465,066 shs	5.61 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	-1.36%	-1.36%	+2.84%	+14.17%	-22.46%
JATT JATT Acquisition	-2.54%	+3.60%	+12.75%	-9.09%	-65.98%
XBIT XBiotech	-2.44%	+12.00%	-3.78%	-9.68%	-42.74%
ZURA Zura Bio	-8.70%	-7.08%	+5.27%	-17.00%	-67.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLLS Cellectis	3.0161 of 5 stars	3.5	3.0	0.0	0.0	2.6	2.5	0.6
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	0.6219 of 5 stars	0.0	0.0	0.0	0.0	3.5	2.5	0.6
ZURA Zura Bio	2.9069 of 5 stars	3.6	3.0	0.0	0.0	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	3.00	Buy	$4.00	175.86% Upside
JATT JATT Acquisition	0.00	N/A	N/A	N/A
XBIT XBiotech	0.00	N/A	N/A	N/A
ZURA Zura Bio	3.13	Buy	$14.33	1,265.08% Upside

Current Analyst Ratings Breakdown

Latest JATT, ZURA, CLLS, and XBIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$49.22M	1.64	N/A	N/A	$2.36 per share	0.61
JATT JATT Acquisition	N/A	N/A	$0.04 per share	27.08	($0.53) per share	N/A
XBIT XBiotech	$4.01M	21.29	N/A	N/A	$5.98 per share	0.47
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
XBIT XBiotech	-$38.53M	-$1.29	N/A	∞	N/A	N/A	-21.14%	-19.55%	8/11/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	8/12/2025 (Estimated)

Latest JATT, ZURA, CLLS, and XBIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	XBIT XBiotech	N/A	-$0.36	N/A	-$0.36	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	0.44	1.67	1.67
JATT JATT Acquisition	N/A	0.15	0.15
XBIT XBiotech	N/A	29.15	29.15
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
JATT JATT Acquisition	47.97%
XBIT XBiotech	55.70%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
JATT JATT Acquisition	20.00%
XBIT XBiotech	33.10%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
XBIT XBiotech	100	30.49 million	20.40 million	Optionable
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

JATT, ZURA, CLLS, and XBIT Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Average PT from Analysts

June 21, 2025 | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Buy" by Analysts

June 18, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on Zura Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)

June 3, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.comS

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 25, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

Zura Bio initiates Phase II systemic sclerosis treatment trial

December 25, 2024 | msn.com

Zura Bio Limited (NASDAQ:ZURA) Director Sells $2,734,458.09 in Stock

November 28, 2024 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT, ZURA, CLLS, and XBIT Company Descriptions

Cellectis NASDAQ:CLLS

$1.46 -0.02 (-1.53%)

As of 06/27/2025 04:00 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

JATT Acquisition NYSE:JATT

$1.15 -0.03 (-2.54%)

As of 06/26/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

XBiotech NASDAQ:XBIT

$2.80 -0.07 (-2.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.79 -0.01 (-0.36%)

As of 06/27/2025 06:44 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Zura Bio NASDAQ:ZURA

$1.05 -0.10 (-8.70%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.12 +0.07 (+6.57%)

As of 06/27/2025 05:44 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time